REGENXBIO Management
Management criteria checks 2/4
REGENXBIO's CEO is Ken Mills, appointed in Mar 2009, has a tenure of 15.08 years. total yearly compensation is $5.92M, comprised of 11.4% salary and 88.6% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth $4.42M. The average tenure of the management team and the board of directors is 7.4 years and 7.7 years respectively.
Key information
Ken Mills
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 11.4% |
| CEO tenure | 15.1yrs |
| CEO ownership | 0.6% |
| Management average tenure | 7.4yrs |
| Board average tenure | 7.7yrs |
Recent management updates
Recent updates
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%
Aug 03Regenxbio: Patience And Regular Homework Are Keys
Jul 12REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates
Jun 27The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business
May 12Regenxbio: Is The Ultimate Catalyst Coming?
Apr 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$677k | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$261m |
| Jun 30 2023 | n/a | n/a | -US$274m |
| Mar 31 2023 | n/a | n/a | -US$270m |
| Dec 31 2022 | US$6m | US$651k | -US$280m |
| Sep 30 2022 | n/a | n/a | US$74m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$101m |
| Dec 31 2021 | US$9m | US$632k | US$128m |
| Sep 30 2021 | n/a | n/a | -US$212m |
| Jun 30 2021 | n/a | n/a | -US$145m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$8m | US$613k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$91m |
| Jun 30 2020 | n/a | n/a | -US$135m |
| Mar 31 2020 | n/a | n/a | -US$103m |
| Dec 31 2019 | US$6m | US$596k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$64m |
| Jun 30 2019 | n/a | n/a | -US$49m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$5m | US$546k | US$100m |
| Sep 30 2018 | n/a | n/a | US$80m |
| Jun 30 2018 | n/a | n/a | US$78m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$3m | US$530k | -US$73m |
Compensation vs Market: Ken's total compensation ($USD5.92M) is above average for companies of similar size in the US market ($USD3.46M).
Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.
CEO
Ken Mills (48 yo)
15.1yrs
Tenure
US$5,916,712
Compensation
Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer, President and Director at REGENXBIO Inc., (formerly REGENX Biosciences, LLC) since March 2009. Mr. Mills was a Partner at FOXK...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 15.1yrs | US$5.92m | 0.56% $ 4.4m | |
| Executive VP & CFO | 14.7yrs | US$2.62m | 0.38% $ 3.0m | |
| Executive VP & COO | no data | US$2.95m | 0.051% $ 403.9k | |
| Executive VP & Chief Scientific Officer | 7.1yrs | US$2.99m | 0.059% $ 461.7k | |
| Executive VP & Chief Medical Officer | 5yrs | US$3.31m | 0% $ 0 | |
| Executive VP & Chief Legal Officer | 7.7yrs | US$3.44m | 0.046% $ 366.7k | |
| Chief Communications & People Officer | 6.5yrs | no data | no data | |
| Executive Vice President of Intellectual Property | 7.9yrs | no data | no data | |
| Executive VP of Commercial Strategy & Operations | 5.7yrs | no data | no data |
7.4yrs
Average Tenure
54.5yo
Average Age
Experienced Management: RGNX's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 15.1yrs | US$5.92m | 0.56% $ 4.4m | |
| Independent Director | 8.5yrs | US$339.98k | 0.0061% $ 48.5k | |
| Independent Director | 2.6yrs | US$339.98k | 0.0061% $ 48.5k | |
| Lead Independent Director | 8.9yrs | US$352.48k | 0.0061% $ 48.5k | |
| Member of Scientific Advisor | no data | no data | no data | |
| Chairman of the Board | 15.2yrs | US$354.98k | 6.45% $ 50.9m | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.9yrs | US$327.48k | 0.0061% $ 48.5k | |
| Independent Director | 7.7yrs | US$334.98k | 0.0061% $ 48.5k | |
| Independent Director | 2.6yrs | US$324.98k | 0.0061% $ 48.5k | |
| Independent Director | 1.8yrs | US$329.98k | 0.0041% $ 32.3k |
7.7yrs
Average Tenure
69yo
Average Age
Experienced Board: RGNX's board of directors are considered experienced (7.7 years average tenure).